Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights
--Webcast and conference call today at 4:30 p.m. ET -- BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months
Toggle Summary Aimmune to Present at the Wedbush PacGrow Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 6, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas , M.D., will present at the Wedbush
Toggle Summary Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Recent Operational Highlights
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, August 8, 2019 , at 4:30 p.m.
Toggle Summary Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 11, 2019-- Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company
Toggle Summary Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency
Toggle Summary Aimmune to Present at the JMP Securities Life Sciences Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 12, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas , M.D., will present at the JMP
Toggle Summary Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
Company to Share Updated Clinical Data on AR101 and Provide Perspective on Its Value to Society BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 11, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, will present at the
Toggle Summary Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 5, 2019-- Aimmune Therapeutics, Inc.  (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman
Toggle Summary Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
--APPEAL 2: Struggle to Avoid Accidental Peanut Exposure Negatively Impacts Quality of Life for Patients and Families-- --Phase 3 PALISADE Follow-on Study Analysis: Improvements in Quality of Life for Peanut-Allergic Patients after Continued AR101 Treatment-- LISBON, Portugal --(BUSINESS
Toggle Summary New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
--Patients tolerated as much as 2,000 mg of peanut protein with fewer adverse events -- --Favorable ongoing and notable immunological changes observed over time-- LISBON, Portugal --(BUSINESS WIRE)--Jun. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing